Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
1998-08-14
2008-01-29
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C435S320100, C435S235100, C435S471000, C435S456000, C424S233100
Reexamination Certificate
active
07323177
ABSTRACT:
This invention relates to a recombinant vector including a recombinant porcine adenovirus, stably incorporating and capable of expression of at least one heterologous nucleotide sequence. The nucleotide sequence is preferably one which encodes an antigenic determinant of Hog Cholera Virus or Pseudorabies virus. The further invention relates to a method of production of recombinant vectors, to methods of preparation of vaccines based on the vectors, to administration strategies and to methods of protecting pigs from disease.
REFERENCES:
patent: 6492343 (2002-12-01), Reddy et al.
patent: 714867 (1995-02-01), None
patent: WO 95/0269 (1995-01-01), None
patent: WO 96 10642 (1996-04-01), None
patent: WO 97/20036 (1997-06-01), None
patent: WO 99/08706 (1999-02-01), None
patent: WO 99 53047 (1999-10-01), None
Konig et al. Classical Swine Fever Virus: Independent Induction of Protective Immunity by Two Structural Glycoproteins Journal of Virology (1995) vol. 69, No. 10, pp. 6479-6486.
Field et al. In Fields Virology ed. Field et al. Lippincott-Raven Publishers. (1996) pp. 2164-2166.
Callebant, P. et al., “Construction of a recombinant adenovirus for the expression of the glycoprotein S antigen of porcine respiratory coronavirus,” (1994)Coronavirus469-470.
Gorziglia, M. and Kapikian, A.Z., “Expression of the OSU rotavirus outer capsid protein VP4 by an adenovirus recombinant,” (1992)J. Virology66(7):4407-4412.
Kleiboeker, S.B. et l., “Genomic cloning and restriction site mapping of a porcine adenovirus isolate: demonstration of genomic stability in porcine adenovirus,” (1993)Arch. Virol.133:357-368.
Reddy, P.S. et al., “Restriction endonuclease analysis and molecular cloning of porcine adenovirus type 3,” (1993)Intervirology36:161-168.
Reddy, P.S. et al., “Sequence analysis of putative pVIII, E3 and fibre regions of porcine adenovirus type 3,” (1995)Virus Research36:97-106.
Reddy, P.S. et al., “Porcine adenoviruses types 1, 2 and 3 have short and simple early E-3 regions,” (1996)Virus Research43:99-109.
Torres, J.M. et al., “Induction of antibodies protecting against transmissible gastroenteritis coronavirus (TGEV) by recombinant adenovirus expressing TGEV spike protein,” (1995)Virology213:503-516.
Torres, J.M. et al., “Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus,” (1996)J. Virology70(6):3770-3780.
Adam, M. et al., “Vaccination of pigs with replication-defective adenovirus vectored vaccines: the example of psuedorabies,” (1994)Vet. Microbiology, 42:205-215.
Bett, A.J. et al., “An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,” (1994)Proc. Natl. Acad. Sci. USA, 91:8802-8806.
Callebaut, P. et al., “Development of a recombinant vector virus for vaccination against viral diarrhoea and respiratory disease in pigs,” (1992) Mededelingen van de Faculteit Landbouwwetenschappen Universiteit Gent, Gent, BE, 57(4B):2077-2084.
Chartier, C. et al., “Efficient generation of recombinant adenovirus vectors by homologous recombination inEscherichia coli,” (Jul. 1996)J. Virology, Am. Soc. Microbiology, 70(7):4805-4810.
Graham, F.L. et al., “Methods for construction of adenovirus vectors,” (1995)Molecular Biotechnology3(3):207-220.
Mittal et al., “Development of a bovine adenovirus type 3-based expression vector,” (1995)J. General Virology, Soc. for General Microbiology, 76:93-102.
Tuboly, T. et al., “Restriction endonuclease analysis and physical mapping of the genome of porcine adenovirus type 5,” (1995)Virus Research, Amsterdam, NL 37(1):49-54.
Tuboly, T. et al., “Potential viral vectors for the stimulation of mucosal antibody responses against enteric viral antigens in pigs,” (1993)Res. in Vet. Sci., British Vet. Assn., London, GB, 54(3): 345-350.
Xu, Z.Z. et al., “Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences,” (1997)Virology230:62-71.
Shenk, Thomas, “Adenoviridae: The Viruses and Their Replication,”Fields Virology, Third Edition, Chapter 67, (1996), pp. 2111-2148.
Imler et al.; “Trans-Complementation of E1-Deleted Adenovirus: A New Vector to Reduce the Possibility of Codissemination of Wild-Type and Recombinant Adenoviruses,”Human Gene Therapy, vol. 6, pp. 711-721, Jun. 1995.
Horwitz, Marshall S.; “Adenoviruses,”Fields Virology, Third Edition, Chapter 68, (1996), pp. 2149-2171.
Graham et al.; “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,”Journal of General Virology, vol. 36, pp. 59-74, (1977).
Derbyshire et al.; “Serological and Pathogenicity Studies With Some Unclassified Porcine Adenoviruses,”Journal of Comparative Pathology,vol. 85 (3), Jul. 1975, pp. 437-443.
Hirahara et al.; Isolation of Porcine Adenovirus from the Respiratory Tract of Pigs in Japan,Japan Journal of Veterinary Science, vol. 52(2), pp. 407-409, (1990).
Reddy et al.; “Characterization of the Early Region 4 of Porcine Adenovirus Type 3,”Virus Genes, vol. 15(1), pp. 87-90, (1997).
McCoy et al.; “Nucleotide and amino acid sequence analysis of the porcine adenovirus 23K protein,”DNA Sequence—The Journal of Sequencing and Mapping, vol. 6, pp. 251-254, (1996).
Kleiboeker, Steven B.; “Sequence analysis of putative E3, pVIII, and fiber genomic regions of a porcine adenovirus,”Virus Research, vol. 31, (1994), pp. 17-25.
Bett et al.; “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors,”Journal of Virology, vol. 67(10), Oct. 1993, pp. 5911-5921.
Reddy et al.; “Development of porcine adenovirus-3 as an expression vector,”Journal of General Virology, vol. 80, (1999), pp. 563-570.
Reddy et al.; “Porcine adenoviruses types 1, 2 and 3 have short and simple early E-3 regions,”Virus Research, vol. 43, (1996), pp. 99-109.
Li et al.; “Analysis of early region 4 of porcine adenovirus type 3,”Virus Research, vol. 104, (2004), pp. 181-190.
Crouzet et al.; “Recombinational construction inEscherchia coliof infections adenoviral genomes,”Proc. Natl. Acad. Sci. USA, vol. 94, pp. 1414-1419, Feb. 1997.
He et al.; “A simplified system for generating recombinant adenoviruses,”Proc. Natl. Acad. Sci. USA, vol. 95, pp. 2509-2514, Mar. 1998.
Ketner et al.; “Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone,”Proc. Natl. Acad. Sci. USA, vol. 91, p. 6186-6190, Jun. 1994.
Kring et al.; “Transcription Mapping of Mouse Adenovirus Type 1 Early Region 4,”Virology, vol. 190, pp. 248-255, (1992).
Ball et al.; “Early Region 4 Sequence and Biological Comparison of Two Isolates of Mouse Adenovirus Type 1,”Virology, vol. 180, pp. 257-265, (1991).
Von Seggern et al.; “Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein,”Journal of General Virology, vol. 79, pp. 1461-1468, (1998).
Beard et al.; “Analysis of Early Region 3 Mutants of Mouse Adenovirus Type 1,”Journal of Virology, vol. 70(9), Sep. 1996, pp. 5867-5874.
Hammond et al.; “Vaccination of pigs with recombinant porcine adenovirus expressing the gD gene from pseudorabies virus,”Vaccine, vol. 19, pp. 3752-3758, (2001).
Beard et al.; “Transcription Mapping of Mouse Adenovirus Type 1 Early Region 3,”Virology, vol. 175, pp. 81-90, (1990).
Beard et al.; “Characterization of an 11K Protein Produced by Early Region 3 of Mouse Adenovirus Type 1,”Virology, vol. 208, pp. 457-466, (1995).
Cauthen et al.; “Sequence of the mouse adenovirus type-1 DNA encoding the 100-kDA, 33
Hammond Jeffrey Michael
Johnson Michael Anthony
McCoy Richard J.
Sheppard Michael G.
Howrey LLP
Mosher Mary E.
Vectogen Pty Ltd.
LandOfFree
Recombinant porcine adenovirus vector does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant porcine adenovirus vector, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant porcine adenovirus vector will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3965178